Citius Oncology (CTOR) vs Intercure (INCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Intercure (INCR) has outperformed Citius Oncology (CTOR) over the past year, losing 37.5% versus a loss of 54.6%. Citius Oncology is the larger company by market cap ($88.3 million vs $75.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTOR | INCR |
|---|---|---|
| Share price | $0.835 | $5.03 |
| Market cap | $88.31M | $75.47M |
| 1-day change | -2.45% | -1.95% |
| YTD return | -16.50% | +10.55% |
| 1-year return | -54.62% | -37.52% |
| 5-year return | — | -85.81% |
| EPS (TTM) | $-0.48 | $-0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.25 | $8.40 |
| 52-week low | $0.491 | $3.40 |
| Distance from 52-week high | -62.89% | -40.12% |
| Analyst consensus | none | — |
| Avg. price target upside | +379.04% | — |
| Average volume | 99.72K | 21.73K |
| Shares outstanding | 105.76M | 15.00M |
| Employees | — | 285 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INCR has outperformed CTOR by 17.1 percentage points over the past year.
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees
CTOR vs INCR FAQ
Which is bigger, Citius Oncology or Intercure?
Citius Oncology (CTOR) is larger, with a market capitalization of $88.31M compared with $75.47M for Intercure (INCR).
Which stock has performed better over the past year, CTOR or INCR?
INCR returned -37.52% over the past 12 months, compared with -54.62% for CTOR (price return, excluding dividends). Past performance does not predict future results.
Are Citius Oncology and Intercure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.